https://research.ouhsc.edu/news Parent Page: News id: 26727 Active Page: details id: 26917

News

OUHSC Research News – Monday, April 17, 2023


Published: Friday, April 14, 2023

 

OUHSC Research News – Monday, April 17, 2023

Workshops and Seminars

The Ins and Outs of Participant Support Costs

Date: April 26, 2023

Time: 10:00 -11:00 am

Description: The Grants and Contracts Accounting Office (GCA) and the Office of Research Administration (ORA) will be hosting a virtual workshop to address fundamental concepts related to participant support costs.

Participant support costs are payments to individuals for training through a workshop, conference, seminar, or other short term instructional or information sharing activity that is supported by a sponsored award. This workshop will provide attendees with an understanding of what participant support costs are, who can and cannot be a participant, allowable vs. unallowable costs, etc.

Registration: This is a Zoom event. Registrants will receive the Zoom link prior to the event. Please register here.

Questions: Should you have any questions or need more information, please contact Sogol Rasouli at sogol-rasouli@ouhsc.edu. 

 

Lunch & Learn: New Ventures & Conflict of Interest

Date: Wednesday April 26, 2023; 12:00 p.m. (CDT)

Topics

  • Starting a new venture with OU IP
  • Resources to help with a startup
  • Determining if you have a conflict of interest
  • Managing conflicts of interest

Register here

Office of Technology Commercialization

Website: ou.edu/otc

 

 

OUHSC Funding Opportunities

New Clinical Study Opportunities

Please note this is NOT a solicitation for study subjects

Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:

  • Janssen_Post-ACS Survey_Protocol 70033093ACS3003
  • OG-6219-P001_Organon_Endometriosis_Global_13Mar23_GSID
  • Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
  • Target population: adult patients with MGFA Class II to IVa gMG

Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.

 

Request for applications:  Genetic CRISPR Screening Pilot Award Program from the Oklahoma Nathan Shock Center on Aging and Oklahoma Center for Therapeutic Sciences

The Oklahoma Nathan Shock Center on Aging (NSC) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Pilot Awards in target and pathway discovery in cell-based models of aging and age-associated disease using high throughput screening and arrayed sgRNA CRISPR technologies.  Please see the attached RFA for more details.

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

  • Astellas Pharma is seeking research related to direct reprogramming to achieve transdifferentiation of cells to another functional type in order to discover therapeutic interventions for degenerative diseases. Direct reprogramming of cells to cell types related to CNS, Lung, Heart, Kidney, Liver, Gut, Skin and Eye are of particular interest; all methods of in vivo reprogramming considered. Cell therapy, cell transplantation, biomaterial-based therapy and CRISPR/Cas systems are out of scope. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26).
  • Cumulus Oncology is looking to engage with academics who have highly tumor-restricted antigens or moloclonal or multvalent antibodies that target them with potential for therapeutic activity in cancer. Embryonic cell targets are priority but others considered if sufficient tumor-specific activity to minimize off-target effects.  Solid tumors are highest interest but all cancers are within scope.  Out of scope: drug repurposing, small molecule, small antibodies, ADC, immunotoxins, radioimmunotherapy, gene therapy and call based therapeutics.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26).
  • A global pharmaceutical company is looking to identify novel methods for discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets through passive permeation, endocytosis or via transporters. Novel in vitro assays for prediction of bioavailability/intracellular targeting with proven translation to in vivo models are also of interest.  Out of scope: use of well-known cell-penetrating peptides (unless significant innovation is demonstrated) and drug delivery systems/formulation strategies.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 4/26)
  • Worwag Pharma is seeking novel research and technology related to the role of Vitamin D in human health and applications for prevention and treatment of deficiency.  Approaches of interest include metabolites or analogues, novel combinations, approaches with improved metabolism or mode of action, formulations to improve stability and bioavailability, improved drug delivery systems and self-diagnostic tools and digital solutions.  Out of scope: Vitamin D for use in food fortification. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 5/20)

 

 

NIH Notices 

 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

NIH Funding Opportunities

 

 

Other Funding Opportunities

DoD Lung Cancer Research Program (LCRP)

  • Career Development Award (CDA)
  • Concept Award (CA)

Pre-Application (Letter of Intent): May 2, 2023
Application: May 23, 2023

  • Idea Development Award (IDA)
  • Translational Research Award (TRA)

Pre-Application (Preproposal): May 10, 2023
Application: August 3, 2023

  • Patient-Centered Outcomes and Survivorship Award (PCOSA)

Pre-Application (Letter of Intent): July 20, 2023
Application: August 10, 2023

Link to Full Announcement: https://cdmrp.health.mil/funding/lcrp

 

Cystic Fibrosis (CF) Foundation 

Application Deadline: May 11, 2023

 

CF Foundation NIH K-Boost Award

Description: This award is designed to provide a $50,000 per year supplement to an NIH K-award that has a CF focus.

Application Deadline: Rolling applications must be submitted online at awards.cff.org.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/cf-foundation-nih-k-boost-award                                                                 

 

CF Foundation/NIH K-Unfunded Award

Description: This award is designed to provide support for investigators with meritorious NIH K applications that were not selected for funding as they revise and resubmit.

Application Deadline: Rolling applications must be submitted online at awards.cff.org.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/cf-foundationnih-k-unfunded-award

 

CF Research Additional Mentoring Program (RAMP)

Description: The RAMP Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.

Application Deadline: Applications must be submitted online at awards.cff.org by May 23, 2023.

For questions, please contact Elizabeth Yu (eyu@cff.org). 

Link to Full Announcement: https://www.cff.org/researchers/research-additional-mentoring-program-award

 

The Lung Cancer Research Foundation (LCRF) – Daiichi Sankyo – AstraZeneca Research Grant on Antibody Drug Conjugates

Description: LCRF is pleased to announce a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. This competitive funding mechanism will provide up to $270,000 in funding over a two-year period.

The LCRF - Daiichi Sankyo - AstraZeneca Research Grant on Antibody Drug Conjugates will develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs.

Application Deadline: May 31, 2023

Link to Full Announcement: Complete details including eligibility criteria and application instructions may be found on the LCRF website.

 

Chan Zuckerberg Initiative (CZI) Request for Applications: Ben Barres Early Career Acceleration Award RFA

Description: The Chan Zuckerberg Initiative invites applications for the second cycle of the Ben Barres Early Career Acceleration Awards. This is an investigator award for early career academic investigators, especially those who are new to the field of neurodegeneration. Awards are $1.2M in total costs over 4 years. Early career investigators will benefit from mentored support and resources of the CZI Neurodegeneration Challenge Network.

Letter of Intent (LOI) Deadline: April 20, 2023

Link to Full Announcement: https://chanzuckerberg.com/rfa/ben-barres-early-career-acceleration-awards/

 

Robert A. Winn Career Development Award (Winn CDA)

Description: The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations. The program collaborates with communities to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. It provides emerging investigators the sponsorship, support, and tools they need to conduct clinical trials that will yield new treatments effective in all populations.

Application Deadline: May 12, 2023

Link to Full Announcement: https://diversityinclinicaltrials.org/application-information . Please see the attached flyers.

 

HRSA Nurse Education, Practice, Quality and Retention (NEPQR)-Pathway to Registered Nurse Program (PRNP) (HRSA-23-016)

Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO). The Nurse Education, Practice, Quality and Retention (NEPQR) - Pathway to Registered Nurse Program (PRNP) aims to create a pathway from academic training to clinical practice through the creation and implementation of Licensed Practical Nurse/Licensed Vocational Nurse (LPN/LVN) to Registered Nurse (RN) Bridge Programs and employment of Clinical Nurse Faculty.

HRSA will award approximately $8.9 million to up to 8 cooperative agreements over a period of four years.

Application Deadline: April 27, 2023

Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-016?UTM_campaign=NOFO

 

DoD Ovarian Cancer Research Program (OCRP)

  • Clinical Translational Research Award
  • Clinical Trial Award
  • Ovarian Cancer Clinical Trial Academy - Leadership Award

Pre-Application: May 26, 2023

Application: July 21, 2023

Link to Full Announcement: https://cdmrp.health.mil/funding/ocrp

 

DoD Epilepsy Research Program (ERP)

Pre-Application (Letter of Intent): May 19, 2023

Application: June 23, 2023

Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495101

 

The International Center for Responsible Gaming - REQUEST FOR APPLICATIONS ON RESEARCH ON PRE-COMMITMENT AS A PREVENTION MEASURE TO REDUCE GAMBLING-RELATED HARMS

Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a two-year Large Grant to study the effectiveness of “pre-commitment,” a prevention strategy that encourages gamblers to set limits on money and time spent gambling. Applicants may request up to a total of $75,000 per year for up to two years plus 15 percent in Facilities & Administration costs. Total amount that may be requested is $172,500.

Application Deadline: May 15, 2023

Link to Full Announcement: https://www.icrg.org/information/apply-for-icrg-funding

Documents to download